جستجوی استاد راهنمای دانشگاهی

• Medical Imaging
• Magnetic Resonance Imaging (MRI)
• Molecular Imaging
• +۳ مورد دیگر

Mohammed Salman Shazeeb serves as an Adjunct Teaching Professor in Biomedical Engineering at Worcester Polytechnic Institute (WPI), with affiliated appointments in Radiology at UMASS Medical School and MGH/Harvard Medical School. His academic roles bridge engineering innovation and clinical imaging applications across multiple institutions. His educational foundation includes: BS Biomedical Engineering, Boston University (summa cum laude) MENGR Biomedical Engineering, WPI PhD in BME & Medical Physics, WPI & UMASS Medical School Postdoctoral training in Molecular Imaging (UMASS), MRI Biophysics (MGH/Harvard & UAE University), and Translational Imaging (Sanofi) Professor Shazeeb's research pioneers quantitative MRI methodologies for tissue characterization, with dual focus on biomaterials science and clinical translation. His work develops novel parameters for tracking collagen scaffold integration, hydrogel degradation via CEST MRI, and tumor vasculature analysis. Neuroimaging applications include myelination tracking and manganese-enhanced brain mapping, while cardiac imaging innovations address respiratory motion artifacts through advanced hysteresis modeling. His publication record (2011-2019) reveals a strategic evolution from fundamental MRI physics toward clinically impactful applications, particularly in tissue engineering and oncology. Key contributions include motion correction algorithms adopted in cardiac SPECT/PET and quantitative biomarkers for biomaterial integration. As an Adjunct Teaching Professor, he integrates clinical imaging challenges into WPI's biomedical engineering curriculum. His research collaborations span academic medical centers and industry, with ongoing projects in MRI methodology development. Though no specific awards are documented, his work appears in premier journals including Cancer Research and Biomaterials , reflecting significant contributions to medical imaging science.

• Radiation Oncology
• Breast Cancer Research
• Hodgkin Lymphoma
• +۵ مورد دیگر

Maja Vestmø Maraldo serves as a Clinical Associate Professor in the Department of Clinical Medicine at the University of Copenhagen's Faculty of Health and Medical Sciences. Her clinical work is based at Copenhagen University Hospital (Rigshospitalet), where she contributes to cancer treatment programs and research initiatives in radiation oncology. Dr. Maraldo's research spans multiple critical areas of oncology with particular expertise in: Breast cancer treatment optimization and risk prediction Hodgkin lymphoma survivorship and late effects assessment Pediatric radiation oncology and neurocognitive outcomes Proton therapy applications and patient perspectives Cardiac radiation dose management Reirradiation strategies for challenging cases Her publication record demonstrates an active research program focused on improving cancer treatment through evidence-based approaches that balance clinical effectiveness with patient quality of life considerations. She frequently collaborates on international multicenter studies and Nordic research networks, contributing to both technical advancements in radiation delivery and patient-centered outcomes research. Dr. Maraldo is actively involved with the Danish Breast Cancer Group and participates in several clinical trials evaluating novel radiation therapy approaches. Her work bridges clinical practice with research to optimize treatment protocols while minimizing side effects across multiple cancer types and patient populations.

• Pediatric Oncology
• Neuro-Oncology
• Childhood Brain Tumors
• +۳ مورد دیگر

René Mathiasen serves as a Clinical Associate Professor in the Department of Clinical Medicine at the University of Copenhagen, specializing in Paediatrics with clinical affiliation to the Capital Region of Denmark (Region Hovedstaden). His work integrates pediatric oncology, neurology, and ophthalmology through hospital-based research at Blegdamsvej addresses in Copenhagen. His research focuses on critical diagnostic challenges in childhood cancers, particularly brain tumors and acute myeloid leukemia. Key interests include ophthalmological tumor signs, diagnostic intervals, pandemic impacts on referral systems, and neurocognitive outcomes post-tumor resection. He employs nationwide Danish cohort methodologies and cross-linguistic European collaborations to address misdiagnosis patterns and treatment complications. Mathiasen actively contributes to Nordic pediatric oncology initiatives including the CMS study group and Nordic Society of Paediatric Haematology and Oncology. His recent work demonstrates strong translational focus—from melatonin secretion studies to advanced PET imaging techniques—while leveraging Denmark's comprehensive health registries for population-level analysis.

• Neuropharmacology
• Brain Metabolism
• Alzheimer's Disease Research
• +۴ مورد دیگر

Emil Winther Westi is a Research Fellow at the University of Copenhagen's Faculty of Health and Medical Sciences within the Department of Drug Design and Pharmacology and Molecular and Cellular Pharmacology research group. His work focuses on brain metabolism mechanisms and their implications in neurological disorders. Dr. Westi's research spans critical neuroscience domains: Neuropharmacology and drug design Brain metabolism in health and disease Alzheimer's disease mechanisms and models Stroke pathophysiology and preclinical models Glioma cell metabolism and signaling Cerebrospinal fluid dynamics and choroid plexus function His publication record demonstrates expertise in metabolic mapping of neuronal and glial cells, with emphasis on how metabolic processes change in neurological conditions. He employs advanced techniques including dMRI, immunohistochemistry, and functional metabolic mapping across multiple disease models. Dr. Westi has published in high-impact journals such as Nature Communications, Glia, and Journal of Cerebral Blood Flow and Metabolism. His work has received significant academic attention with multiple papers highlighted in news outlets and social media platforms, indicating strong relevance to current neurological research.

Jude Savarrajمشاهده پروفایل

استادیار

• Neural Engineering
• Epilepsy Research
• Neuromodulation Therapies
• +۷ مورد دیگر

Dr. Jude Savarraj is an Assistant Professor at The University of Texas Health Science Center at Houston (UTHealth Houston), affiliated with the McGovern Medical School's Department of Neurosurgery. His research focuses on neural engineering and epilepsy treatment through neuromodulation therapies, working collaboratively with clinical teams at UTHealth Houston. Dr. Savarraj earned his PhD in Biomedical Engineering from Louisiana Tech University in 2013, with a dissertation focused on neural engineering and electrical signatures associated with glioma spread. He completed postdoctoral training at UTHealth Houston from 2015 to 2018, specializing in clinical informatics. His expertise spans machine learning, big data analysis, and their applications in neuroscience and neurology. His research investigates network dynamics and neuronal responses to chronic brain stimulation, particularly Deep Brain Stimulation (DBS) for epilepsy treatment. He is currently involved in a clinical trial with Dr. Nitin Tandon on neuromodulation for seizure control, evaluating how chronic low-frequency stimulation impacts neuronal network synchronization. His work aims to develop novel approaches to desynchronize overactive brain regions to prevent seizure occurrence. Analysis of Dr. Savarraj's 40+ publications reveals a strong focus on neurological conditions including epilepsy, subarachnoid hemorrhage, and traumatic brain injury. His recent work (2022-2024) shows increasing integration of machine learning techniques with clinical neuroscience, particularly in biomarker discovery and physiological monitoring using federated learning approaches. Dr. Savarraj maintains an active research program with numerous collaborations across UTHealth Houston departments and with external institutions. His work bridges basic neuroscience with clinical applications, aiming to translate scientific discoveries into improved neuromodulation therapies for neurological disorders. His laboratory work focuses on neural engineering approaches to understand and treat epilepsy through advanced stimulation techniques. Dr. Savarraj collaborates extensively with clinicians, particularly in neurosurgery and neurocritical care, to ensure his research addresses clinically relevant questions in neurological disease treatment.

• Magnetic Resonance Imaging
• Advanced Image Reconstruction
• Quantitative MRI Methods
• +۵ مورد دیگر

Tobias Wood serves as a Senior Lecturer in Magnetic Resonance Imaging within Neuroimaging, leading multiple externally funded research initiatives focused on advancing quantitative MRI methodologies. His primary institutional affiliation remains implied through project leadership but is not explicitly stated in available documentation. Research interests span the full spectrum of Magnetic Resonance Imaging with particular emphasis on advanced image reconstruction techniques and quantitative biomarker development . His work bridges engineering innovation with clinical applications in neurological disorders including multiple sclerosis, Parkinson's disease, and Huntington's disease, while also exploring novel frontiers like the neurocutaneous axis in inflammatory skin conditions. The research fingerprint reveals strong concentration in Myelin Imaging (49%), In Vivo Neuroscience (32%), and Parkinson's Disease research (31%). Recent publications demonstrate consistent output in high-impact journals including Magnetic Resonance in Medicine and Neuropsychopharmacology , with emerging focus on ultra-low-field MRI applications and multi-modal biomarker validation. Key trends include methodological innovation in silent scanning protocols, pediatric coil development, and translation of quantitative techniques to clinical monitoring. Current funding portfolio includes five major projects totaling approximately £2.5M, with leadership roles in EPSRC and CHDI Foundation grants. Collaborative networks span 11 similar research profiles with strong connections to multiple sclerosis research, neurodegenerative disorders, and advanced imaging physics communities. Lab resources include access to high-field MRI systems, specialized computational infrastructure, and clinical validation partnerships. Supervision approach emphasizes interdisciplinary training with strong publication expectations and industry-academic career pathways.

• Functional Neurosurgery
• Deep Brain Stimulation
• Brain Connectivity
• +۷ مورد دیگر

Harith Akram serves as an Honorary Clinical Associate Professor and Honorary Senior Research Fellow in the Clinical and Movement Neurosciences department at University College London. As a certified neurosurgeon specializing in functional neurosurgery and deep brain stimulation, he maintains active clinical practice alongside his academic work, as evidenced by his doctors.org.uk email address. Dr. Akram's research focuses on developing translational methods in diffusion and functional MRI brain connectivity to improve the safety and efficacy of neurosurgical interventions. His work spans multiple domains including Parkinson's disease, dystonia, essential tremor, laryngeal dystonia, and neuro-oncology applications. He has made significant contributions to understanding brain connectivity patterns relevant to movement disorders and brain tumors. Analysis of his recent publication record (2023-2025) reveals a strong focus on deep brain stimulation techniques, brain connectivity mapping, and novel applications of imaging in functional neurosurgery. His work demonstrates increasing sophistication in targeting approaches, with publications on directional DBS leads, FAT1-weighted MRI guidance, and network-based targeting for various conditions. Several high-impact papers have emerged from his research, including a Nature Neuroscience publication on mapping dysfunctional circuits in the frontal cortex using DBS. Dr. Akram appears deeply engaged in both clinical innovation and surgical education, with publications addressing anatomical accuracy in surgical nomenclature and methods for optimizing surgical efficiency. His collaborative approach is evident in numerous multicenter studies across different neurological conditions. His clinical and research activities support Sustainable Development Goal 3 (Good Health and Well-Being), with particular emphasis on improving neurological care through advanced neurosurgical techniques and precision targeting based on individual brain connectivity patterns.

Sarah E S Learyمشاهده پروفایل

استاد

• Pediatric brain tumors
• Precision Medicine
• Clinical trials
• +۶ مورد دیگر

Sarah Leary, MD, MS is an Attending Physician and Medical Director of the Pediatric Brain Tumor Program in the Cancer and Blood Disorders Center at Seattle Children's Hospital. She serves as a Professor of Pediatrics at the University of Washington School of Medicine and is an associate of the Fred Hutch Cancer Research Center. Dr. Leary holds the position of Medical Director of Clinical Research at the Ben Towne Center for Childhood Cancer and Blood Disorders Research and leads the Seattle Children's Tumor Banking and Biology study. She also serves as the Seattle Children's site Principal Investigator for the Children's Oncology Group and CONNECT Clinical trials consortia. Dr. Leary completed her MD at University of Tennessee College of Medicine, followed by a Pediatric Residency at Johns Hopkins Hospital, and a Pediatric Hematology/Oncology Fellowship at St. Jude Children's Research Hospital. She further enhanced her research capabilities by earning an MS in Epidemiology from the University of Washington between 2010 and 2014. Dr. Leary's research focuses on clinical trials and novel therapy development for childhood, adolescent and young adult brain tumors. Her recent work emphasizes precision medicine, big data projects, and international collaborations to generate, collect and share molecular and clinical data to support research. She has particular expertise in translational research with a focus on improving outcomes for pediatric brain tumor patients. Her work spans molecular characterization of brain tumors, development of targeted therapies, and innovative immunotherapeutic approaches. Her recent publications demonstrate a strong focus on innovative treatments for pediatric brain tumors, particularly low-grade gliomas and medulloblastoma. Her work spans targeted therapies like RAF inhibitors (tovorafenib), immunotherapies including CAR T-cell approaches, and novel chemotherapy regimens. Much of her research involves leading or participating in major clinical trials through the Children's Oncology Group and other consortia, with an emphasis on molecularly guided treatments that represent the cutting edge of pediatric neuro-oncology. Dr. Leary serves in multiple leadership roles including clinical Vice-Chair of the Central Nervous System Committee of the Children's Oncology Group, chair of the Data Safety Monitoring Committee of the Pediatric Brain Tumor Consortium, and member of the Brain Malignancy Steering Committee of the National Cancer Institute. She leads international data sharing efforts as the lead of the clinical data operations group of the Children's Brain Tumor Network (CBTN) and Co-Chair of the Executive Committee of the INSPiRE consortium, demonstrating her commitment to collaborative research that accelerates progress in the field. Dr. Leary leads the Seattle Children's Tumor Banking and Biology study and is deeply involved with the Ben Towne Center for Childhood Cancer and Blood Disorders Research. Her clinical interests focus specifically on pediatric brain tumors and precision medicine approaches. She is particularly passionate about providing the best care for patients today while working to find cures for every child in the future, as reflected in her statement: 'It is a privilege to work with children, adolescents and young adults as part of a multidisciplinary team of clinicians and researchers who are so dedicated to providing the best care for our patients today while at the same time working to find a cure for every child in the future.'

Erin E Crottyمشاهده پروفایل

استادیار

• Pediatric Neuro-oncology
• Brain Tumor Immunotherapy
• CAR T-cell Therapy
• +۷ مورد دیگر

Dr. Erin E Crotty is an attending physician and pediatric oncologist specializing in brain and spinal cord tumors at Seattle Children's Hospital, where she serves as the clinical oncology lead for the Retinoblastoma Program. She holds an academic appointment as Assistant Professor in the Department of Pediatrics at the University of Washington School of Medicine and is affiliated with the Ben Towne Center for Childhood Cancer and Blood Disorders Research. Her educational background includes an MD from George Washington University School of Medicine & Health Sciences, pediatric residency training at Children's National Medical Center in Washington, D.C., and hematology/oncology fellowship at Seattle Children's Hospital/University of Washington with additional translational research training at Fred Hutch Cancer Research Center. Dr. Crotty's research focuses on bringing innovative therapies to children with difficult-to-treat central nervous system tumors, with particular emphasis on immunotherapies, CAR T-cell approaches, and precision medicine. She leads early phase clinical trials for children with brain tumors and serves as site Principal Investigator for the Pacific Pediatric Neuro-oncology Consortium (PNOC) and the Collaborative Network for Neuro-oncology Clinical Trials (CONNECT). Her clinical work includes moderating Seattle Children's weekly Brain Tumor Board for multidisciplinary case reviews. Analysis of Dr. Crotty's recent publications reveals a strong focus on novel therapeutic approaches for pediatric CNS tumors, particularly CAR T-cell therapies targeting multiple antigens (B7-H3, EGFR, HER2, IL-13Ralpha2), liquid biopsy techniques using CSF for disease monitoring, and molecularly guided treatment strategies for high-grade gliomas and medulloblastoma. Her work bridges translational research with clinical application, emphasizing targeted therapies and immunotherapeutic approaches. Dr. Crotty actively contributes to advancing the field through numerous clinical trials including PNOC022 for diffuse midline gliomas, PNOC028 for natural killer cell therapy, and SC-9017 for pediatric low-grade glioma. Her leadership in the Brain Tumor Program at Seattle Children's demonstrates commitment to bringing laboratory discoveries directly to patient care.

Nicholas A Vitanzaمشاهده پروفایل

دانشیار

• Pediatric Neuro-Oncology
• Brain Tumor Research
• CAR T Cell Therapy
• +۶ مورد دیگر

Nicholas A Vitanza is an Associate Professor in Hematology/Oncology at Seattle Children's Hospital, where he serves as an Attending Pediatric Neuro-Oncologist in the Cancer and Blood Disorders Center. He is also the Principal Investigator at the Ben Towne Center for Childhood Cancer and Blood Disorders Research and has been on staff since August 2016. Dr. Vitanza directs the Vitanza Lab and serves as the Scientific Director of the Brain Tumor Research Program, overseeing a dedicated research program spanning laboratory work to patient care, and as the CNS CAR T Cell Lead, overseeing CAR T cell trials for brain and spinal cord tumor patients. Dr. Vitanza completed his medical education at the American University of the Caribbean School of Medicine, followed by residency training at the State University of New York at Stony Brook. He then completed fellowships at multiple prestigious institutions including Lucile Salter Packard Children's Hospital-Stanford, New York University Langone Medical Center, and Stanford University School of Medicine. His specialized training in pediatric oncology and neuro-oncology was conducted under renowned mentors including Drs. Bill Carroll, Elizabeth Raetz, and Michelle Monje. Dr. Vitanza's research focuses on developing targeted therapies for children with fatal brain and spinal cord tumors, particularly diffuse intrinsic pontine glioma (DIPG), diffuse midline glioma (DMG), and atypical teratoid rhabdoid tumor (ATRT). His work spans from high-throughput drug screening in patient-derived models to clinical translation, with a particular emphasis on CAR T cell immunotherapies. He has pioneered multiple innovative clinical trials including BrainChild-01 (targeting HER2), BrainChild-02 (targeting EGFR), BrainChild-03 (targeting B7-H3), and BrainChild-04 (multi-antigen targeting). Analysis of Dr. Vitanza's recent publications reveals a strong focus on advancing CAR T cell therapies for pediatric CNS tumors, with particular emphasis on combination approaches, multi-targeting strategies, and addressing treatment-related toxicities. His work bridges basic science discoveries with clinical applications, consistently aiming to translate laboratory findings into novel therapeutic options for children with previously untreatable brain cancers. The publications demonstrate progressive refinement of delivery methods, target selection, and safety profiles of immunotherapies for pediatric brain tumors. R37 MERIT (Method to Extend Research in Time) Award from NIH National Cancer Institute Invited researcher to Cancer Moonshot Brain Tumor Forum at White House (2023) ASPHO award during pediatric oncology fellowship Dr. Vitanza has secured significant NIH funding for his research and has directed multiple clinical trials that have advanced the field of pediatric neuro-oncology. His laboratory work has led to multiple clinical trials, demonstrating a successful translational pipeline from bench to bedside. He has mentored numerous researchers and clinicians in the field of pediatric brain tumor research and treatment. The Vitanza Lab focuses on creating treatment-naïve biopsy-derived patient-derived DIPG/DMG models, discovering targetable molecular and immunologic vulnerabilities in these tumors, and translating these findings into innovative new clinical trials. The lab collaborates extensively with other research groups at Seattle Children's Hospital and beyond, forming a comprehensive research ecosystem dedicated to curing childhood brain cancers.

Joelle Payne Straehlaمشاهده پروفایل

استادیار

• Cancer nanomedicine
• Drug delivery technologies
• Pediatric brain tumors
• +۵ مورد دیگر

Dr. Joelle Payne Straehla is an Assistant Professor of Pediatrics at the University of Washington School of Medicine and an Adjunct Assistant Professor of Bioengineering. She serves as a principal investigator at Seattle Children's Research Institute and as a pediatric oncologist in the Brain Tumor Program at Seattle Children's Hospital. Dr. Straehla is also a member of the Fred Hutch/University of Washington/Seattle Children's Cancer Consortium. Dr. Straehla received her MD from Northwestern University Feinberg School of Medicine and completed her pediatric residency at Seattle Children's Hospital/University of Washington. She further completed a fellowship in pediatric hematology/oncology at Dana-Farber/Boston Children's Cancer and Blood Disorders Center, where she gained additional training in biological and chemical engineering in the laboratory of Dr. Paula Hammond at Massachusetts Institute of Technology. Prior to joining Seattle Children's in 2024, she was an Instructor of Pediatrics at Harvard Medical School and a Charles W. (1955) and Jennifer C. Johnson Clinical Investigator at MIT's Koch Institute for Integrative Cancer Research. Dr. Straehla's research focuses on advancing drug delivery technologies for pediatric cancers, with a special interest in cancer nanomedicine. Her work operates at the intersection of nanotechnology and cancer biology, aiming to bridge the gap between innovative engineering tools and clinical practice. She leads the Straehla Lab, which is dedicated to designing new nanoparticle-based therapeutics, identifying biological regulators of nanoparticle drug delivery, improving delivery across challenging tissue barriers, and developing strategies to remodel the tumor microenvironment. Her research has significant implications for improving treatment of pediatric brain tumors and other difficult-to-treat childhood cancers. Dr. Straehla's publication record demonstrates expertise in nanoparticle design, blood-brain barrier penetration, and targeted cancer therapies. Her work includes developing predictive microfluidic models of glioblastoma, identifying biomarkers for nanoparticle delivery (particularly SLC46A3), and engineering layer-by-layer nanoparticles for improved brain tumor targeting. Her research combines high-throughput screening, genomic analysis, and translational approaches to accelerate the development of nanomedicine for pediatric cancer patients. Among her notable recognitions is the Charles W. (1955) and Jennifer C. Johnson Clinical Investigator position at MIT's Koch Institute for Integrative Cancer Research. Her work has been published in high-impact journals including Science, Proceedings of the National Academy of Sciences, and ACS Nano. As a clinician, Dr. Straehla cares for children with brain and spinal cord tumors and is involved in local and national consortia focused on improving brain tumor drug delivery through collaborative research. She is committed to harnessing cutting-edge engineering methods to improve outcomes for children with cancer while minimizing side effects to the developing brain. The Straehla Lab operates at the Ben Towne Center for Childhood Cancer and Blood Disorders Research and includes a diverse team of researchers working on various aspects of nanomedicine and drug delivery. Current projects include unlocking the drivers of nanoparticle delivery, engineering combination nanomedicines, and developing precision drug carriers for the central nervous system.

Bonnie L Coleمشاهده پروفایل

استادیار بالینی

• Pediatric Pathology
• Laboratory Medicine
• Neuropathology
• +۳ مورد دیگر

Bonnie L Cole, MD is a Clinical Assistant Professor and Anatomic Pathologist at the University of Washington School of Medicine, affiliated with Seattle Children's Hospital. She has been on staff since August 2011 and is part of the Center for Clinical and Translational Research. Her primary office is located at Seattle Children's Pathology Lab at 4800 Sand Point Way NE, Seattle, WA. Dr. Cole completed her medical education at the University of Utah School of Medicine in Salt Lake City, UT, and also attended Stanford University. She completed her residency and fellowship in Pathology at the University of Washington in Seattle, WA. She is board certified in Pediatric Pathology and Anatomic/Clinical Pathology. Dr. Cole's research focuses on pediatric pathology, particularly pediatric brain tumors and CNS embryonal tumors. Her clinical interests include pediatric pathology and laboratory medicine, with significant contributions to neuropathology and molecular characterization of tumors. She has been actively involved in cutting-edge research on CAR T-cell therapy for pediatric CNS tumors and therapeutic approaches for diffuse intrinsic pontine glioma. Her work bridges laboratory medicine with clinical applications to improve diagnostic accuracy and treatment strategies for pediatric cancers. Analysis of Dr. Cole's publications reveals a strong focus on pediatric neuro-oncology, particularly brain tumors in children. Her research spans from fundamental neuropathology to clinical applications of novel therapies like CAR T-cells. She has contributed significantly to clinical guidelines for pediatric CNS cancers and has published extensively on molecular characterization of tumors. Her work demonstrates a progression from basic pathology to translational research with direct clinical applications, particularly in immunotherapy approaches for difficult-to-treat pediatric brain cancers. Dr. Cole has been involved in multiple clinical trials and collaborative research projects, including the BrainChild02 phase 1 clinical trial examining CAR T-cell therapy for pediatric CNS tumors. She has contributed to Children's Oncology Group studies and NCCN Clinical Practice Guidelines. Her research has been supported by institutional funding from Seattle Children's and collaborative grants with other pediatric cancer research centers. She actively collaborates with multidisciplinary teams including oncologists, neurosurgeons, and immunotherapy specialists to advance treatments for pediatric brain tumors. As part of the Center for Clinical and Translational Research at Seattle Children's, Dr. Cole works within a comprehensive research ecosystem focused on translating laboratory discoveries into clinical applications. She collaborates with the Ben Towne Center for Childhood Cancer and Blood Disorders and participates in the neuro-oncology research team. Her work contributes to Seattle Children's position as a leading institution for pediatric cancer research and treatment, particularly in the area of brain tumors and innovative cellular therapies.

Juliane Gustمشاهده پروفایل

استادیار

• Pediatric Neurology
• Neuroimmunology
• CAR T-cell Therapy
• +۶ مورد دیگر

Dr. Juliane Gust is an Assistant Professor in the Department of Neurology, Division of Pediatric Neurology at the University of Washington School of Medicine. She serves as an Attending Physician at Seattle Children's Hospital and is a Principal Investigator at the Norcliffe Foundation Center for Integrative Brain Research. Dr. Gust holds both an MD and PhD in Neurobiology from the University of Washington, where she also completed her Child Neurology residency training. Dr. Gust's research focuses on understanding how cancer treatments and inflammation affect the developing brain, with particular emphasis on CAR T-cell therapy for pediatric brain tumors. Her work addresses critical challenges in treating diffuse intrinsic pontine glioma (DIPG) and other central nervous system tumors in children. She leads the Gust Lab which investigates neurotoxicity mechanisms associated with immunotherapies and develops strategies to protect children's brains during cancer treatment. Her extensive publication record demonstrates a strong focus on CAR T-cell therapies for pediatric CNS tumors, with particular attention to neurotoxicity patterns, imaging findings, and novel delivery methods. Her research shows how locoregional CAR T-cell delivery can overcome blood-brain barrier limitations, and she has pioneered the classification of tumor inflammation-associated neurotoxicity (TIAN) as a distinct syndrome from traditional immune effector cell-associated neurotoxicity. Dr. Gust has been instrumental in several groundbreaking clinical trials including BrainChild-03 (testing B7-H3 CAR T-cells for DIPG) and BrainChild-04 (pioneering quad-targeting CAR T-cell therapy). Her work bridges clinical practice with laboratory research, aiming to improve outcomes for children with previously untreatable brain cancers while minimizing neurological complications. As both a clinician and researcher, Dr. Gust is deeply committed to improving care for children with brain tumors. Her passion statement reflects this dedication: 'A brain injury is one of the biggest challenges a family can face, and I'm honored to care for them and support them during this difficult time. As a physician, I strive to give each child the best possible care, and to help families make important medical decisions and find comfort and resilience. As a researcher, I'm driven to understand the brain's mysteries and to find new ways to protect it so more children can lead happy, healthy lives.'